The global Hemostatic Spray Market is estimated to be valued at US$ 2.51 Bn in 2023 and is expected to exhibit a CAGR of 9.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Hemostatic agents play a crucial role in controlling bleeding during surgeries and trauma-related injuries. Hemostatic sprays contain active clotting ingredients that form a clot when sprayed onto a bleeding surface, allowing surgeons to treat bleeding wounds rapidly and effectively. They are widely used in emergency and trauma settings as well as in operating rooms for managing intraoperative bleeding. The growing adoption of minimally invasive procedures and rising number of surgical procedures being performed are major factors driving the demand for hemostatic sprays.
Market Overview:
Hemostatic sprays manage blood loss through wounds and incisions by accelerating the body’s natural clotting response. They offer advantages over traditional methods like gauze packing as they can be easily applied through a fine mist directly onto bleeding sites. Their use allows for better visualization and fewer dressings required during or after a procedure.
Market key trends:
One of the key trends in the Hemostatic Spray Market Demand is the rising popularity of tissue sealants. Tissue sealants help manage bleeding from vascular structures by forming a mechanical seal over the puncture site. They offer advantages such as faster and more effective hemostasis compared to compression methods alone. Furthermore, tissue sealants avoid the risk of hematoma formation associated with traditional compression techniques. Key players are focusing on developing novel tissue sealant formulations that are easy to apply and help reduce procedure times. For instance, in 2021, Arch Therapeutics received FDA approval for its AC5 Advanced Wound System, a novel hemostatic device that forms a protective seal over wounds.
Segment Analysis
The global hemostatic spray market can be segmented based on product, application, end-user and region. Based on product, the market is segmented into thrombin-based hemostatic agents, combination hemostatic agents, oxidized regenerated cellulose-based hemostatic agents and gelatin-based hemostatic agents. The thrombin-based hemostatic agents segment is expected to dominate the market over the forecast period due to their high effectiveness and ease of application in minor and major surgeries.
Key Takeaways
The global hemostatic spray market is expected to witness high growth, exhibiting a CAGR of 9.0% over the forecast period, due to increasing prevalence of chronic diseases and rising number of surgical procedures performed globally.
Regional analysis
North America is expected to dominate the global hemostatic spray market over the forecast period. This is mainly attributed to rising geriatric population, increasing volume of surgical procedures and presence of major players in the region. Asia Pacific is expected to exhibit the highest CAGR during the forecast period owing to increasing healthcare expenditure, rising medical tourism and growth in the number of private hospitals in emerging countries such as China and India.
Key players
Key players operating in the hemostatic spray market are Baxter, Ethicon, CSL Behring, Pfizer, Johnson & Johnson, Celox Medical, HemCon Medical Technologies, Medtrade Products, Z-Medica, RevMedx, Axio Biosolutions, Cohera Medical, Teleflex Incorporated, Integra LifeSciences Corporation, Tricol Biomedical, Biomâ€TMUp, Arch Therapeutics, Hemostasis, Starch Medical, Success Pharmaceutical. Baxter is one of the prominent players offering hemostatic spray product TachoSil to control bleeding during surgeries.
Read More:
